| Former Sequenom Executive Charged With Faking It Derek Lowe submits: I wrote here about Sequenom (SQNM), a company which claimed to have developed an in vitro test for Downs Syndrome. The whole story dissolved into a heap of lawsuits, allegations of fraud, questions about whether Sequenom ever had such a test at all, and other craziness. Now the SEC has charged a former executive of the company with lying to investors. Elizabeth Dragon publicly touted the accuracy of the company's test several times, in front of large groups, before the roof came in. Here's the official complaint, and it's most interesting reading:Complete Story » seekingalpha.com |
IPO Market Sizzles - In China The Burrill Report submits: Wondering if the IPO window is open? Well there’s no doubt about it if you are talking about the IPO market in China. The life sciences sector has raised $6.1 billion through initial public offerings in the past 12 months, far outpacing the activity in the United States. And, despite the collapse of Charles River's (CRL) $1.6 billion acquisition of Wuxi (WX), M&A activity is growing.We spoke to Greg Scott, president and founder of the consulting firm ChinaBio and publisher of ChinaBio Today, about the thriving IPO market for life sciences companies there, how that’s evolved over the past year and what the outlook is moving forward.Complete Story » seekingalpha.com |
Biogen Pays Pretty Price to Expand ALS Pipeline EP Vantage submits:The list of unpartnered amyotrophic lateral sclerosis (ALS) treatments just got smaller. Biogen Idec (BIIB) has snapped up the phase III-ready neuroprotective drug KNS-760704 for $20m in cash and a $60m stake in privately-held Knopp Neurosciences, allowing the partners to advance the compound into pivotal trials in the first half of next year.As a result of the deal, KNS-760704 will join the now closely-watched olesoxime, which was cornered by Actelion (ALIOF.PK) earlier this month, in phase III trials for ALS. Mitsubishi Tanabe's edaravone and CytRx's arimoclomol are also in late stage studies. ALS patients currently have just one pharmaceutical treatment option, riluzole, which has modest benefits, so this deal increases the number of shots on goal for the fatal and debilitating disease. (Therapeutic focus – ALS field entering pivotal stage, August 2, 2010.)Complete Story » seekingalpha.com |
FDA to Revoke Knee-Device Approval The FDA said it planned to revoke a medical-device company's right to sell a knee implant called Menaflex after an unprecedented yearlong review concluded the agency erred in allowing it on the market. online.wsj.com |
Senior Veterans Reflect - Video Veterans Share Life Lessons Learned in Service feedproxy.google.com |